Is Naxitamab injection included in medical insurance?

那西妥单抗注射液（Naxitamab）是一种针对癌胚分化抗原GD2二唾液酸神经节苷脂的IgG1单克隆抗体。 GD2 is normally expressed during fetal development and in mature neurons, pain fibers, and skin cells and is a highly effective target in the treatment of neuroblastoma. It is ubiquitously expressed in neuroblastoma (and other neuroectodermal tumors) and rarely undergoes antigen loss.

Nasitumumab injection received accelerated approval from the FDA in November 2020 for the treatment of high-risk neuroblastoma (a cancer most common in young children) that is relapsed or refractory (unresponsive to previous treatments) in the bone or bone marrow. The approval requires noxitum The monoclonal antibody injection is co-administered only with granulocyte-macrophage colony-stimulating factor (GM-CSF), a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of the monoclonal antibody injection therapy significantly simpler than that of its predecessor. This medication should only be taken by or under the direct supervision of a physician and may cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor.按照建议，在每次输注那西妥单抗注射液前预先用药。根据严重程度，降低速率、中断输注或永久停止那西妥单抗注射液。

It is understood that noxituzumab injection has been approved in China, but it has not been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of Naxituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.